Article ; Online: Successful Treatment of Life-Threatening COVID-19 Infection in a Face Transplant Recipient.
2021 Volume 87, Issue 1, Page(s) 105–106
Abstract: ... vary considerably. Furthermore, research pertaining to transplant recipients, COVID-19 infection, and ... the first reported VCA recipient with COVID-19 infection that received anti-IL-6 immunotherapy resulting ... has been reported in severe COVID-19 infections, and treatment with anti-IL-6 (tocilizumab) has ...
| Abstract | Abstract: Recent literature suggests that severe COVID-19 is associated with an exaggerated immune response during viral infection, resulting in cytokine storm. Although elevated plasma interleukin 6 (IL-6) has been reported in severe COVID-19 infections, and treatment with anti-IL-6 (tocilizumab) has demonstrated promising outcomes both domestically and abroad, reports remain limited and therapeutic regimens vary considerably. Furthermore, research pertaining to transplant recipients, COVID-19 infection, and anti-IL-6 therapy remains underdeveloped. Herein, we report the successful treatment of the only reported facial vascularized composite allograft (VCA) recipient who contracted severe COVID-19 and the first reported VCA recipient with COVID-19 infection that received anti-IL-6 immunotherapy resulting in an excellent recovery despite his multiple preexisting and COVID-19-related comorbidities-adult respiratory distress syndrome, acute renal failure requiring hemodialysis, and concomitant sepsis due to extensive drug-resistant bacterial pneumonia upon presentation. To date, he has not demonstrated any anti-IL-6 drug-related adverse effects. This preliminary report also suggests that our immunosuppressed VCA patients can indeed demonstrate a robust cytokine response during COVID-19 infection and may also respond favorably to emerging anticytokine immune therapies. We hope that our experience proves helpful to other centers that might encounter critically ill VCA recipients in the ongoing COVID-19 pandemic and in the years to follow. |
|||||
|---|---|---|---|---|---|---|
| MeSH term(s) | Adult ; COVID-19 ; Cytokine Release Syndrome ; Humans ; Male ; Pandemics ; SARS-CoV-2 ; Transplant Recipients | |||||
| Language | English | |||||
| Publishing date | 2021-03-04 | |||||
| Publishing country | United States | |||||
| Document type | Journal Article | |||||
| ZDB-ID | 423835-7 | |||||
| ISSN | 1536-3708 ; 0148-7043 | |||||
| ISSN (online) | 1536-3708 | |||||
| ISSN | 0148-7043 | |||||
| DOI | 10.1097/SAP.0000000000002790 | |||||
| Shelf mark |
|
|||||
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1419: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.